NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial

C Chuntao Gao Y Yanqiao Zhang X Xiujuan Qu X Xingyun Chen J Jingdong Zhang H Heshui Wu M Meili Sun (Central Hospital Affiliated to Shandong First Medical University, Jinan, China) Y Yong Zha J Junbin Wang Y Yusheng Wang Z Zhihua Li J Jinghua Gao R Rongbo Lin A Aimin Zang (Department of Oncology, Affiliated Hospital of Hebei University, Baoding, China) H Huiqing Zhang X Xianglin Yuan C Chengyou Du J Jun Zhao (Department of Thoracic Oncology Beijing Cancer Hospital Beijing China) Y Yongsheng Yang X Xuetao Shi W Wei Cheng B Bangmao Wang S Shikai Wu T Tiansuo Zhao J Jian Wang S Song Gao X Xiuchao Wang W Weidong Ma R Rui Liu Y Yehui Shi Y Yanping Liu Y Yijiao Xie M Miao Niu F Fuchen Zhao J Jun Yu (Department of Earth System Science, University of California) J Jihui Hao